Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:39 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
NCT05358249 · Novartis Pharmaceuticals · PHASE1/PHASE2 · terminated · last registry update 2026-10-21 · Non-small cell lung cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Business reasons and not based on any safety concerns.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against MAP2K2 in non-small cell lung cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-08-11Results posted on the registry: National Cancer Institute (NCI), Atezolizumab + Cobimetinib (NCT03600701)
- 2026-07-28Results posted on the registry: M.D. Anderson Cancer Center, Durvalumab + Selumetinib (NCT03581487)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-04-08Also stopped (terminated): Deciphera Pharmaceuticals, LLC, Inlexisertib + Trametinib (NCT04892017)
- 2026-03-18Results posted on the registry: M.D. Anderson Cancer Center, Bintrafusp Alfa + Pimasertib (NCT04789668)
- 2026-03-18Also stopped (terminated): M.D. Anderson Cancer Center, Bintrafusp Alfa + Pimasertib (NCT04789668)
- 2026-01-09Also stopped (terminated): Pfizer, Sasanlimab Prefilled syringe + Encorafenib (NCT04585815)
- 2025-11-04Results posted on the registry: Novartis Pharmaceuticals, Dabrafenib + Trametinib (NCT04452877)
- 2025-10-23Results posted on the registry: Pfizer, PF-07284890 + Binimetinib (NCT04543188)
- 2025-10-23Also stopped (terminated): Pfizer, PF-07284890 + Binimetinib (NCT04543188)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision